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Abstract
In Sub-Saharan Africa, malaria remains a major cause of morbidity and mortality among children
under 5, due to lack of access to prompt and appropriate diagnosis and treatment. Many countries
have scaled-up community health workers (CHWs) as a strategy towards improving access. The
present study was a cost-effectiveness analysis of the introduction of malaria rapid diagnostic tests
(mRDTs) performed by CHWs in two areas of moderate-to-high and low malaria transmission in
rural Uganda. CHWs were trained to perform mRDTs and treat children with artemisinin-based
combination therapy (ACT) in the intervention arm while CHWs offered treatment based on pre-
sumptive diagnosis in the control arm. Data on the proportion of children with fever ‘appropriately
treated for malaria with ACT’ were captured from a randomised trial. Health sector costs included:
training of CHWs, community sensitisation, supervision, allowances for CHWs and provision of
mRDTs and ACTs. The opportunity costs of time utilised by CHWs were estimated based on self-
reporting. Household costs of subsequent treatment-seeking at public health centres and private
health providers were captured in a sample of households. mRDTs performed by CHWs was asso-
ciated with large improvements in appropriate treatment of malaria in both transmission settings.
This resulted in low incremental costs for the health sector at US$3.0 per appropriately treated
child in the moderate-to-high transmission area. Higher incremental costs at US$13.3 were found
in the low transmission area due to lower utilisation of CHW services and higher programme costs.
Incremental costs from a societal perspective were marginally higher. The use of mRDTs by CHWs
improved the targeting of ACTs to children with malaria and was likely to be considered a cost-
effective intervention compared to a presumptive diagnosis in the moderate-to-high transmission
area. In contrast to this, in the low transmission area with low attendance, RDT use by CHWs was
not a low cost intervention.
Keywords: Malaria, Community health workers, Community case management, Rapid diagnostic test, Artemisinin-based combin-
ation therapy, Cost-effectiveness analysis, Uganda
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Introduction
Malaria remains a major cause of morbidity and mortality among
children in sub-Saharan Africa, despite the presence of effective and
low cost interventions including artemisinin-based combination
therapy (ACT) and insecticide-treated bednets (Jones et al. 2003;
Black et al. 2010; Liu et al. 2012; WHO 2015). An important reason
for this failure to prevent malaria deaths is that children with fever
do not access effective interventions or access them at a late stage
(Jones et al. 2003; Darmstadt et al. 2005; Haines et al. 2007).
Prompt diagnosis and appropriate treatment are crucial elements in
reducing mortality, but can be hampered by the long distances fami-
lies have to travel to reach the nearest public health facility and inad-
equate treatment services available at these facilities due to recurring
stock-outs of antimalarials, staff shortages or a lack of diagnostic
capacity for parasitological confirmation (Kamal-Yanni et al. 2012).
Many malaria-endemic countries are characterised by a shortage of
health workers and geographical inequities in access, with rural and
hard-to-reach areas particularly underserved in terms of health ser-
vices (WHO 2006). A thriving private sector partially fills this gap
and common practice in Africa is to treat episodes of fever with
over-the-counter medication purchased at drug retail outlets. Yet
this may increase the risk of substandard treatment practices; e.g.
sale of cheaper ineffective antimalarials rather than ACT, sale of
partial doses, or sale of antimalarial drugs without parasitological
confirmation (Whitty et al. 2008; Kamal-Yanni et al. 2012).
Against this background, increased deployment of community
health workers (CHWs) has been seen as a promising strategy to-
wards diminishing these problems (Haines et al. 2007; Young et al.
2012; Perry et al. 2014). While programs differ between countries,
common features of CHWs are that they are usually volunteers re-
cruited from their community; receive a short training; and work for
little or no compensation (Ruizendaal et al. 2014). These character-
istics have led to the expectation that CHWs can significantly ex-
pand access to key health services to underserved populations,
deliver interventions promptly and at a lower cost than other health
cadres in terms of salary and training.
Several studies have shown that CHWs are able to deliver
prompt, appropriate malaria treatment in their communities (Sirima
et al. 2003; Chinbuah et al. 2006; Staedke et al. 2009; Okwundu
et al. 2013) and achieve cure rates above 90% among children with
malaria parasites (Ajayi et al. 2008). The presence of CHWs can
also result in reduced workload in public sector health facilities
(Tiono et al. 2008; Lal et al. 2015). Following WHO guidelines that
all suspected malaria cases should be parasitologically confirmed
and treated with ACT if positive (WHO 2010), research has demon-
strated CHWs’ capability to perform a malaria rapid diagnostic test
(mRDT), interpret the result correctly and prescribe an appropriate
treatment (Hawkes et al. 2009; Mubi et al. 2011; Chanda et al.
2011a; Counihan et al. 2012; Thiam et al. 2012; Ndyomugyenyi
et al. 2016); although a range of factors can reduce success, includ-
ing insufficient training (Harvey et al. 2008), accuracy of the mRDT
utilised (Ruizendaal et al. 2014) and tendency to disregard negative
mRDT results (Elmardi et al. 2009; Ruizendaal et al. 2014).
Less evidence is available on cost and cost-effectiveness of
CHWs trained to diagnose and treat malaria, and studies vary con-
siderably in the methodology chosen in terms of categories of costs
included, effectiveness measure utilised and the diagnostic method
of the CHWs (Vaughan et al. 2015). Using a Markov model and so-
cietal perspective cost data from Uganda, Lubell et al. (2010) con-
cluded that presumptive diagnosis and treatment by CHWs would
likely be cost-effective versus health facility care in high malaria
transmission areas, but less likely in low transmission settings.
Conversely, the incremental societal cost per disability-adjusted life
year averted was found to be US$90.3 for an intervention where
CHWs diagnosed children presumptively for malaria and treated
with ACT relative to standard care at public health facilities and
over-the-counter drugs in private outlets in Ghana (Nonvignon et al.
2012). Later studies, in which CHWs were trained to perform
mRDTs and treat positives with ACT were also found to be more
cost-effective than facility-based management in Zambia, where the
provider cost per case correctly treated was US$4.2 and US$6.1 re-
spectively (Chanda et al. 2011b). Cost per life saved for CHWs
equipped with mRDTs and ACTs was slightly higher than manage-
ment at public health facilities in Ethiopia (US$2258 versus
US$2150) from a provider perspective (Gaumer et al. 2014).
However, when analysed from a societal perspective, CHWs had a
slightly lower cost per life saved than health facilities (US$884 ver-
sus US$922) due to household-level benefit in saved out-of-pocket
spending. Compared to presumptive treatment, the potential eco-
nomic benefits of mRDTs could include: cost-savings through
reduced overuse of ACTs and improved patient outcomes resulting
from targeting of ACTs to malaria cases, and detection of non-
malarial fevers.
The present research presents a cost and cost-effectiveness ana-
lysis based on data from two cluster-randomised controlled trials to
investigate the effect on appropriate malaria management of train-
ing CHWs to perform mRDT diagnosis in children and treat with
ACT, in two areas with different levels of malaria transmission risk
in rural Uganda (Ndyomugyenyi et al. 2016). We present the results
of a comprehensive costing methodology including government pro-
vider cost, time cost of CHWs involved and costs incurred by
Key Messages
• Involving community health workers (CHWs) is seen as a promising strategy towards improving access to prompt and
appropriate diagnosis and treatment of malaria in Sub-Saharan Africa but cost-effectiveness information is limited.
• Cost-effectiveness analyses of introducing malaria rapid diagnostic tests (mRDTs) performed by CHWs on children under
five and treatment with artemisinin-based combination therapy (ACT) was compared to a presumptive diagnosis in a
moderate-to-high and a low malaria transmission area in rural Uganda.
• The introduction of mRDTs by CHWs resulted in a substantial improvement in appropriate treatment of malaria in both
transmission settings.
• The incremental health sector cost of introducing mRDTs was estimated at US$3.0 per appropriately treated child under
five (US$3.6 from a societal perspective) in the moderate-to-high transmission area and at US$13.3 (US$14.9 from a so-
cietal perspective) in the low transmission area.
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households from initial CHW consultation and additional treatment
seeking over the next 14 days.
Methods
Study area and population
The trials and cost data collection were conducted in Rukungiri
District, South-Western Uganda, inhabited by the Bahororo and
Bakiga ethnic groups, whose main occupation is subsistence farm-
ing. This district has a wide altitudinal range resulting in diverse
malaria transmission patterns within the same district. Two sub-
counties were selected as trial sites: Bwambara sub-county, a lower
altitude area bordered by Lake Edward, which was meso-endemic
for malaria with moderate-to-high transmission, and Nyakishenyi
sub-county, a highland area with low transmission. All villages in
the two sub-counties were invited to participate in the trial; a total
of 63 villages in Bwambara and 64 villages in Nyakishenyi, ranging
between 981–1203 and 1064–2157 metres above sea level in each
sub-county respectively (Ndyomugyenyi et al. 2016).
Study design
Cost-effectiveness analysis was conducted alongside two cluster-
randomised controlled trials involving community-level provision of
treatment for malaria in children under five by CHW volunteers.
Details of the trials are described elsewhere (Ndyomugyenyi et al.
2016; www.actconsortium.org/RDThomemanagement). In brief:
the primary trial objective was to evaluate the impact of mRDTs
used by CHWs (intervention) compared to presumptive clinical
diagnosis by CHWs (control) on the proportion of patients receiving
appropriately-targeted ACT treatment; all villages in each sub-
county were invited to participate; a public meeting was held in each
village to explain the purpose of the research and community mem-
bers asked to select three CHWs per village. Using village as the unit
of randomisation, villages within each transmission area were ran-
domly allocated to either the intervention or control arm and CHWs
in a village all belonged to the same study arm.
CHWs in both study arms were trained to recognise signs and
symptoms of malaria, how to administer antimalarial treatment to
children under five, and when to refer. Half the villages (interven-
tion villages) were randomised to receive an additional one-day
training in malaria diagnosis using mRDTs and to give an ACT only
after a positive test result. CHWs were trained to treat mRDT-
positive children with danger signs with rectal artesunate pre-
referral treatment, and refer these children to the nearest public
health facility. CHWs were also trained to refer, irrespective of the
test result, if the child had any danger signs or other specific listed
symptoms. Artemether-lumefantrine (AL) and mRDTs were pro-
vided at no cost to participating CHWs, and CHW services were
free to community members. CHWs in the control arm offered iden-
tical services, except that diagnosis of malaria was based on clinical
signs and symptoms only, as was the decision to refer children.
Additional supporting interventions included community sensi-
tisation to convey key messages such as: not all fevers are malaria
and hence a diagnostic test was advisable before treatment with
ACT, and that mRDTs were available at government health facili-
ties and from some CHWs. For the first four months after training,
close support supervision visits were provided regularly by the re-
search team to assist CHWs with problems or questions related to
their services. Supervision was scaled back after this initial period.
No formal remuneration was given to CHWs for their services, but
CHWs did receive a monthly soap and paraffin allowance, and bi-
cycles to facilitate their collection of supplies and to attend supervi-
sion meetings.
Estimation of effect
Measurement of effect was determined from the cluster-randomised
trials (Ndyomugyenyi et al. 2016). Data were collected on all chil-
dren under five who presented with fever to a CHW during the trial
period. Treatment decisions made by CHWs were evaluated against
the results of later microscopy of a reference blood slide collected at
each consultation. Slides were examined twice by two experienced
laboratory technicians and discrepant results were resolved by a
third technician blinded to previous results. The measure of effect
was ‘appropriate treatment of malaria with ACT’, which was a com-
posite indicator defined as: a child under five with malaria parasites
in their blood (confirmed by expert microscopy) who received a
course of ACT or rectal artesunate, or a child with a negative mi-
croscopy result who was not prescribed an artemisinin-based treat-
ment. This indicator was developed to be able to measure the
targeting of ACT exclusively to those patients with malaria parasites
in their blood. Previous research studies have utilised this indicator
to assess the impact of introducing mRDTs on appropriate malaria
treatment including in public health centres in two areas of Ghana
(Ansah et al. 2013; Baiden et al. 2016), in private drug shops in
Uganda (Mbonye et al. 2015) and in public health centres in
Afghanistan (Leslie et al. 2014). For the present research, the pro-
portion of children treated appropriately by CHWs in each study
arm, within each transmission setting, was measured over a
12-month period from January-December 2011.
Estimation of costs
The value of resources utilised in each study arm was measured
from both public health sector and societal perspectives and pre-
sented separately. Costs measured from the societal perspective
incorporated the value of time committed by the CHWs, costs borne
by households and health sector costs. All cost figures were adjusted
to the 2011 price level using an annual inflation rate of 8.8% corres-
ponding to the average annual increase in the GDP deflator in
Uganda from 2004 to 2013 and presented in US dollars
(UGX2523¼US$1) (World Bank 2015).
Health sector costs
Total costs of resources for training of CHWs, supervision, and
community sensitisation were considered a health sector cost since
the government would need to fund these activities if the interven-
tion was to be implemented at scale. Personnel costs of these activ-
ities were obtained through interviews with staff who were asked
about their gross monthly salary and to estimate the number of days
spent on these activities. All other costs were captured from the fi-
nancial accounting system of the research project. Training of
CHWs, including the initial period of close support supervision, and
community sensitisation can be expected to have a useful lifespan
beyond the evaluation period of a single calendar year and were
treated as capital goods with annual equivalents calculated assuming
a lifespan of 5 years and a real discount rate of 3% (Walker and
Kumaranayake 2002). The less intense routine supervision con-
ducted during the 12-month evaluation period was considered a re-
current cost and measured for the 2011 calendar year.
mRDTs, drugs and other consumables were supplied free to
CHWs and the cost of acquiring these commodities was also con-
sidered a health sector cost. The mRDT used, First ResponseVR , was
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available in Uganda in 2011 at US$0.87 per test, including shipping.
Adding an assumed wastage rate of 5%, and costs of sterile gloves,
cotton wool, and spirit additionally needed to perform the test, re-
sulted in a unit cost of US$1.00 per mRDT performed. The median
price per course of ACT treatment with AL as well as rectal artesu-
nate was obtained from an international drug price list
(Management Sciences for Health 2012). A recommended ten per-
cent was added for shipping (Management Sciences for Health
2012) and another 12.5% to cover storage and quality control in-
country (personal communication, Central Medical Stores).
Assuming 10% wastage, the estimated cost per course of AL in
2011 was US$0.77 for a child below 3 years of age and US$1.63 for
a child aged 3–7 years, and US$0.74 for a treatment with rectal arte-
sunate. Bicycles and petroleum lamps supplied to CHWs were val-
ued at prevailing local prices in Uganda.
Since CHWs were trained to refer children with danger signs to
the nearest public health facility, costings were carried out for two
public health centres in each transmission setting with the aim of
estimating the treatment cost per health facility visit for referred
children. Recurrent expenditure for each health centre for the finan-
cial year 2011/12 was obtained from the Rukungiri District Office.
Capital expenditure was estimated as the annualised value (Walker
and Kumaranayake 2002) of the construction cost of health centre
buildings and 2011 purchase prices of the main equipment and fur-
niture found at the four health centres visited. A discount rate of
0.03 and expected life spans of 7, 10 and 30 years were used for
equipment, furniture and buildings respectively. Following the
standard step-down costing method (Conteh and Walker 2004;
Drummond et al. 2005), aggregate health centre level costs for
2011/12 were allocated in a step-wise fashion to overhead services
(i.e. administration, cleaning) and intermediate services (dispensary,
diagnostics) and finally to patient services (direct patient care). The
step-down costing was supplemented by micro-costing methods
(Brouwer et al. 2001) in order to separate out the cost of diagnosis
by mRDT and treatment of malaria and non-malaria fevers in the
outpatient departments of the health centres. The cost of the recom-
mended drugs and doses for treatment of a child under five were
estimated using an international price list (Management Sciences for
Health 2012), assuming that health workers generally followed offi-
cial clinical guidelines (Ministry of Health 2010). Relevant person-
nel were interviewed to estimate time required per outpatient
treated, which was then valued according to salary level of the per-
sonnel. Combining the data collected through the standard step-
down and micro costing methods resulted in the unit cost per visit
for the treatment of malaria and non-malarial fever which incorpo-
rated both cost of direct resource input (e.g. drugs and personnel
time) as well as the cost of overhead activities and support activities
from four public health facilities.
Costs borne by community health workers
CHWs invested time in the programme without receiving any formal
monetary remuneration. The opportunity cost of their time was val-
ued at US$1.21 per day corresponding to the GDP per capita per day
in 2011 (World Bank 2015); a value that was assessed as part of the
sensitivity analysis. The rationale behind this choice was the human
capital approach according to which the value of time of an individual
is equal to what he/she contributes to society in the form of the mar-
ket value of output produced by the individual in his/her normal
work (Shillcutt et al. 2009). This approach was modified for this re-
search by setting the value of time as equal for all individuals (irre-
spective of their normal work) at the level of GDP per capita – the
average contribution of Ugandans to output. Time utilised to diagnose
and treat a child and for overhead activities such as travel and time
spent attending supervisory meetings and collecting supplies was cap-
tured from interviews with a subset of CHWs.
Household costs
Household costs in families with a sick child were captured for a
two-week period starting from the initial visit at a CHW. Trained
interviewers visited families two weeks after CHW treatment and
interviewed the main caregiver of the child to capture information
on all out-of-pocket expenditure in this period, including: costs
incurred at the time of initial CHW visit, completed referrals to pub-
lic health facilities, any additional treatment-seeking at private sec-
tor providers, and special foods purchased for the sick child; as well
as time utilised for treatment-seeking and days the main caregiver
was unable to perform their normal activities due to caring for the
child. Lost time was valued at US$1.21 per day. Household costs
were measured in a sample of 413 families: 293 households in the
moderate transmission setting (133 and 160 in the mRDT and pre-
sumptive arms respectively) and 120 in the low transmission setting
(47 and 53 in each arm). Sample size for household cost interviews
was calculated to test a hypothesis that out-of-pocket expenditure
would be lower in the mRDT arm. To detect a decrease of at least
30% in mean out-of-pocket expenditure in the intervention arm
from a mean cost of UGX3500 in the control arm, in a trial with
10 clusters per arm and assuming k¼0.25, power of 80%, and sig-
nificance level of 5%, required 250 interviews per arm (Hayes and
Bennett 1999).
Cost-effectiveness analysis
Data on the costs and effects were linked through a decision analyt-
ical approach (Briggs et al. 2006) using the decision trees displayed
in Figure 1a and b. Identical decision tree structures were used in
the two transmission settings. Probabilities of individual decision
tree branches indicating malaria status (reference microscopy),
mRDT accuracy (sensitivity and specificity), presumptive diagnosis,
adherence to mRDT result and decision by households to follow re-
ferral advice were derived using the data available from the trial
(Ndyomugyenyi et al. 2016). The probability of additional
treatment-seeking in the private sector was captured from the sub-
sample of caregivers interviewed to capture household costs. At the
end of each decision tree, treatment of a child with fever was classi-
fied as appropriate or not according to the study definition used for
the primary trial outcome. Decision tree probabilities differed by the
arm and transmission setting and have been listed in Supplementary
File 1a and 1b.
Health sector and societal costs by study arm in each transmis-
sion setting were calculated by populating the decision trees with
cost per CHW visit estimates as described above. Annualised costs
estimated for community sensitisation, training, supervision, allow-
ances and supplies for CHWs were divided by the number of visits
to CHWs by the arm and setting in the 12-month period January-
December 2011. These average cost per visit estimates therefore
depended on the number of children seen in a particular arm and
setting. Cost per referral visit to public health centres for treatment
of malaria and non-malarial fevers entered the decision model as an
average of the unit costs obtained from the four health centres
included in facility costing. Average household out-of-pocket ex-
penditure per event and the opportunity cost of time lost per illness
episode were obtained from the 413 household cost interviews.
Health Policy and Planning, 2017, Vol. 32, No. 5 679
All costs per event estimates utilised in the decision model are listed
in Supplementary File 1a and 1b.
Total health sector and societal costs and number of
appropriately-treated children were calculated by letting 1000 chil-
dren pass through the populated decision tree for each arm and
transmission setting. The incremental cost-effectiveness ratio (ICER)
was obtained by subtracting total costs in the control arm from the
total costs in the intervention arm (numerator) and subtracting the
total effect measured as appropriately treated children in the control
arm from the total effect in the intervention arm (denominator). The
ICER for each transmission setting therefore measured the extra
cost per additional appropriately treated child when CHWs are
given mRDTs for diagnosis instead of making a presumptive diagno-
sis based solely on signs and symptoms.
Adherence ACT given Appropriate
mRDT positive
Non-adherence No treatment Inappropriate
Subsequent
Malaria * treatment-seeking
Adherence No treatment Inappropriate
mRDT negative
Non-adherence ACT given Appropriate
dlihC
with fever
at CHW Completed referral
Private sector visit
Adherence ACT given Inappropriate
mRDT positive
Non-adherence No treatment Appropriate
Non-malaria * Subsequent
treatment-seeking
Adherence No treatment Appropriate
mRDT negative
Non-adherence ACT given Inappropriate
* According to expert microscopy on a blood slide collected by the community health worker from the child at the time of the visit
   and read later by the research team.
Presumptive malaria ACT given Appropriate Subsequent
Malaria * treatment-seeking
Presumptive non-malaria No treatment Inappropriate
dlihC
with fever
at CHW Completed referral
Private sector visit
Presumptive malaria ACT given Appropriate
Non-malaria * Subsequent
Presumptive non-malaria No treatment Inappropriate treatment-seeking
* According to expert microscopy on a blood slide collected by the community health worker from the child at the time of the visit
   and read later by the research team.
(a)
(b)
Figure 1. (a) Decision model for children under five visiting community health workers offering malaria diagnosis by rapid diagnostic test and (b) Decision model
for children under five visiting community health workers offering presumptive malaria diagnosis.
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Sensitivity analysis
One-way sensitivity analyses were performed by changing the values
of individual parameters and assumptions in the decision models to
observe the effect on the ICER. The parameters assessed included
malaria prevalence among patients seen; accuracy of mRDT; adher-
ence to test results; prices of mRDTs and ACTs; the opportunity
cost of lost time; and cost per visit to public health centres. In add-
ition, since CHWs in the low transmission area saw substantially
fewer patients than CHWs in the moderate-to-high transmission set-
ting, a sensitivity analysis was performed assuming that one CHW
per village (rather than three) would be sufficient to meet service de-
mand in communities with low malaria transmission.
Probabilistic sensitivity analysis (PSA) was undertaken to assess
the sensitivity of the ICER to simultaneous variation in relevant par-
ameters (Briggs et al. 2006) by defining probability distributions to
selected decision model parameters rather than point estimates. Beta
distributions were used for all the branch probabilities used in the
decision trees using trial data to estimate distribution parameters
(Ndyomugyenyi et al. 2016). Due to the non-negative, right-skewed
nature of the household cost data, gamma distributions were used to
describe the variation in these costs (Briggs et al. 2006) with distri-
bution parameters obtained from the household cost survey inter-
views. Other cost parameters (e.g. health centre cost per visit)
entered the analysis as point estimates as there were insufficient data
available to derive the distributions. All distributions and point esti-
mates used in the PSA are shown in Supplementary Material,
Table S1a and b. Simultaneous selection of values from these param-
eter distributions and point estimates, followed by calculation of
ICERs, was performed 10 000 times in Excel (Microsoft, Seattle) in
order to propagate uncertainty in the ICERs (Doubilet et al. 1984).
Uncertainty surrounding the ICERs was summarised by plotting
joint incremental costs and incremental effects in the cost-
effectiveness plane, and quantified by calculating confidence inter-
vals and cost-effectiveness acceptability curves (CEACs) (Lo¨thgren
and Zetraeus 2000; O’Brien and Briggs 2002; Fenwick et al. 2004)
which show the probability that use of mRDTs to inform the man-
agement of malaria by CHWs is cost-effective for different levels of
a health policy maker’s hypothetical willingness-to-pay (WTP) for
an appropriately treated child under five.
Ethical approval
This study was approved by the Uganda National Council for
Science and Technology and the London School of Hygiene &
Tropical Medicine Ethics Committee. Patients refusing an mRDT
test received presumptive treatment. The study was registered with
ClinicalTrials.gov. Identifier NCT01048801 on 13th January 2010.
Results
Cost and effects are presented for a standard population of 1000
children under five visiting CHWs by study arm for each transmis-
sion setting. In the moderate-to-high transmission area, use of
mRDTs to diagnose malaria rather than by symptoms alone resulted
in a substantial increase in the number of appropriately treated chil-
dren of 485 per 1000 (95% CI 453 to 516) (Table 1a). The extra
cost from a health sector perspective in the mRDT arm compared to
the presumptive arm was US$1,462 per 1000 children (95% CI
US$1,424 to US$1,500) leading to an ICER of US$3.0 (95% CI
US$2.8 to US$3.3). In other words, use of mRDT diagnosis in con-
trast to presumptive diagnosis would cost the health sector US$3.0
per additional appropriately treated child under five. Applying a
broader societal perspective incorporating health sector and house-
hold costs, the extra cost in the mRDT arm compared to the pre-
sumptive arm was US$1,755 per 1000 children (95% CI -US$7,740
to US$10 705) leading to an ICER of US$3.6 (95% CI -US$15.8 to
US$22.5). In the low transmission setting (Table 1b), the perform-
ance of mRDT diagnosis resulted in an even greater increase in the
number of appropriately treated children of 822 per 1000 (95% CI
785 to 848) compared to presumptive diagnosis. This improvement
was mainly due to the high proportion of children not suffering
from malaria that were not prescribed an ACT. Extra health sector
cost in the mRDT arm compared to the presumptive arm was
US$10 924 per 1000 children (95% CI US$10 878 to US$10 973)
leading to an ICER of US$13.3 (95% CI US$12.9 to US$13.8). In
the low transmission setting, diagnosing malaria using mRDTs in-
stead of presumptive diagnosis would therefore cost the health sec-
tor US$13.3 per additional appropriately treated child under five.
The extra societal cost in the mRDT arm compared to the presump-
tive arm was US$12 283 per 1000 children (95% CI US$2,783 to
US$21 759) leading to an ICER of US$14.9 (95% CI US$3.4 to
US$26.4).
In the moderate-to-high transmission setting, the health sector
bore over 60% of the total societal cost (in both arms) with supervi-
sion and allowances for CHWs constituting the most important cost
drivers. The cost of consumables (mRDTs, ACTs and other supplies)
amounted to 22% of the total societal cost in both arms, with the
additional costs of mRDTs being largely offset by savings in the cost
of ACTs in the intervention arm. Use of mRDTs was associated with
an increased probability of referral and seeking additional care at
public health centres (4.5% in the mRDT arm and <0.1% in the
presumptive arm), resulting in increased costs for both the public
health sector and households in the mRDT arm. The probability of
households seeking further care at private sector providers was also
higher in the mRDT arm: 8.7% vs. 5.0% in the presumptive arm,
comprising 3% and 2% of societal cost respectively. Overall, ap-
proximately one third of the total societal cost was borne by house-
holds with an opportunity cost of self-reported time required to look
after an ill child as the most important component. The opportunity
cost of CHWs’ time contributed only 3% to the total societal cost in
both arms.
The health sector cost in the low transmission setting constituted
a much larger share of total societal cost at 82% and 77% in the
mRDT and presumptive arms respectively. The distribution of costs
was similar to the moderate-to-high transmission setting, with
supervision and allowances for CHWs being the largest cost compo-
nent. The probability of seeking additional care at public health
centres was 8.7% and 1.8% in the mRDT and presumptive arms re-
spectively, resulting in<1% of the total societal cost in both arms.
The probability of seeking further care at private suppliers like drug
shops and the local mission hospital was 35.7% and 11.4% in the
mRDT and presumptive arms, resulting in 5% and 3% of societal
cost respectively. The opportunity cost of CHWs’ time comprised
2% of the total societal cost in both arms. Although overall house-
hold cost constituted a lower share of societal cost in the low trans-
mission area (16-21%), the opportunity cost of self-reported time
spent caring for a sick child was again the most important
component.
Levels of cost varied across settings and arms. Absolute health
sector cost in the low transmission area was much higher than in
the moderate-to-high transmission setting (both arms) (Tables 1a
and 1b). Similarly, health sector cost in mRDT arms in both trans-
mission settings was higher than the presumptive arms. This was a
reflection of differences in consultation rates observed during the
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2011 evaluation period (Ndyomugyenyi et al. 2016) where more
children sought care in the moderate-to-high transmission area com-
pared to the low transmission site, and fewer children visited CHWs
with mRDTs than CHWs offering presumptive treatment (in both
settings). Some health sector activities, including community sensi-
tisation, training, supervision and allowances and equipment for
CHWs are determined primarily by the number of treatment pro-
viders, rather than the number of patients. The average cost per
child was as a consequence higher in study arms with fewer children
seen in the evaluation period thus explaining some of the differences
in health sector cost by arm and setting.
One-way sensitivity analyses for the moderate-to-high transmis-
sion setting showed that the ICERs from both the health sector and
the societal perspectives were robust to changes in most parameters
investigated with a few important exceptions (Table 2a). Increasing
malaria prevalence among children with fever to 50% rather than the
30-38% observed, resulted in an ICER which was two-fold higher
than the central estimate making mRDT diagnosis by CHWs less at-
tractive from a cost-effectiveness perspective. Decreasing adherence to
negative mRDT results from the observed 98% to 70% or below had
a large upward effect on the ICERs, making mRDTs less cost-
effective. The number of children visiting CHWs was an important
factor influencing the ICER levels. For instance, a 40% increase in
consultations at CHWs with mRDTs, substantially reduced the ICER
from a health sector perspective to US$0.7; and would make mRDTs
more cost-effective relative to presumptive diagnosis.
One-way sensitivity analyses for the low transmission area also
found that the ICERs from both the health sector and the societal
perspectives were robust to changes in most of the parameters inves-
tigated (Table 2b). Malaria prevalence, adherence by CHWs to
mRDT results and attendance of children at CHWs again consti-
tuted the only exceptions. Given the low attendance rate in the low
transmission area, it is possible that one CHW rather than three
would be sufficient to handle the current demand which could lead
to cost savings with respect to training, supervision and allowances
and equipment for CHWs (Supplementary Material, Table S2).
Overall, this additional sensitivity analysis indicated a much lower
ICER from a health sector perspective of US$5.4 (95% CI US$5.2 to
Table 1a. Costs and effects in a standard population of 1000 children suspected of malaria by study arm and incremental cost-effectiveness
ratio (ICER) of replacing presumptive diagnosis by rapid diagnostic tests performed by community health workers in a moderate-to-high
transmission area in Rukungiri District, Uganda, 2011 (US$1¼UGX2,523)
—— mRDT arm —— – Presumptive arm –
N % N %
Children suspected of malaria 1,000 100 1,000 100
Malaria (according to reference diagnosis) 378 38 302 30
Treated with ACT 375 38 994 99
Appropriately treateda 793 79 308 31
US$ % US$ %
Health sector cost per 1000 children 5,674 65 4,213 60
Community sensitisation 143 2 112 2
Trainingb 408 5 273 4
Supervision 1,227 14 697 10
Allowances for CHWs 1,609 18 1,270 18
Equipment for CHWs 363 4 286 4
mRDTs supplied 933 11 0 0
ACTs prescribed 489 6 1,208 17
Other supplies 396 5 366 5
Completed referrals to public health centres 106 1 1 0
CHW cost (value of time) per 1000 children 244 3 185 3
Overhead activitiesc 119 1 90 1
Diagnosis and treatment 125 1 96 1
Household cost per 1000 children 2,857 33 2,623 37
CHW visit (initial visit) 36 0 29 0
Completed referrals to public health centres 28 0 0 0
Drugs, fees, travel (private sector visits) 301 3 172 2
Special food to improve health 926 11 1,157 16
Opportunity cost of time lost 1,566 18 1,264 18
Total societal costs per 1000 children 8,776 100 7,021 100
Incremental analysis
(Replace presumptive diagnosis by mRDT diagnosis
in 1000 children suspected of malaria)
Incremental number of appropriately treated [95% CI] 485 [453; 516]
Incremental health sector cost, US$[95% CI] 1,462 [1,424; 1,500]
Incremental societal cost, US$[95% CI] 1,755 [-7,740; 10,709]
ICER health sector perspective, US$[95% CI] 3.0 [2.8; 3.3]
ICER societal perspective, US$[95% CI] 3.6 [-15.8; 22.5]
aChild with a positive reference diagnosis prescribed an ACT or child with a negative reference diagnosis not prescribed an ACT.
bIncluding cost of initial period of close support supervision.
cQuarterly review meetings, collection of supplies, communication with supervisors, etc.
682 Health Policy and Planning, 2017, Vol. 32, No. 5
US$5.7), and US$6.9 (95% CI -US$4.4 to US$18.0) from a societal
perspective compared to the central estimates presented in Table 1b.
Results from the PSAs from both transmission settings are pre-
sented in Figures 2–5. In the moderate-to-high transmission area, all
pairs of incremental health sector costs and effects were situated in
the north-eastern quadrant of the cost-effectiveness plane meaning
that the change in number of appropriately treated children was al-
ways positive and incremental health sector cost always positive if
mRDTs were used (Figure 2a). According to the CEAC derived from
this pattern of pairs of incremental health sector cost and effects
(Figure 2b), the probability of mRDTs being a cost-effective inter-
vention in a community-treatment programme was 46% if a health
policy maker was willing-to-pay (WTP) at least US$3.0 per appro-
priately treated child, increasing to 94% and 100% if WTP was
US$3.2 and US$3.5. This indicates a high probability that mRDTs
would be cost-effective from a health sector perspective even at very
low WTP in the moderate-to-high transmission setting. The PSA
from a societal perspective showed greater uncertainty with respect
to mRDT use as seen by the larger spread of incremental societal
cost and effects (Figure 3a). From a societal perspective, much
higher WTP would be required to deem use of mRDTs to be a cost-
effective intervention (Figure 3b). Assuming that the WTP was
US$5, the probability of mRDT use being cost-effective in the
moderate-to-high transmission area was 61%; increasing to 84%
and 93% if the WTP was US$10 and US$15 respectively.
The PSA conducted for the low transmission area showed a simi-
lar pattern (Figures 4 and 5), though the levels of incremental cost
and effects were generally higher compared to the moderate-to-high
transmission area. Much higher health policy maker WTPs were
required to deem mRDT introduction a cost-effective intervention in
the low transmission area (Figures 4b and 5b). From a health sector
perspective, a policy maker WTP of US$13.5 per appropriately
treated child would lead to a probability of 83% that CHWs using
mRDTs to diagnose malaria was a cost-effective intervention; whilst
from a societal perspective, the probability of mRDTs performed by
CHWs being cost-effective in the low transmission area was 87% if
the WTP was US$20.0.
Discussion
This analysis presents a comprehensive assessment of the economic
effects of introducing mRDT-based diagnosis into community-based
Table 1b. Costs and effects in a standard population of 1000 children suspected of malaria by study arm and incremental cost-effectiveness
ratio (ICER) of replacing presumptive diagnosis by rapid diagnostic tests performed by community health workers in a low transmission
area in Rukungiri District, Uganda, 2011 (US$1¼UGX2,523)
—— mRDT arm —— – Presumptive arm –
N % N %
Children suspected of malaria 1,000 100 1,000 100
Malaria (according to reference diagnosis) 60 6 56 6
Treated with ACT 69 7 968 97
Appropriately treateda 901 90 78 8
US$ % US$ %
Health sector cost per 1000 children 22,971 82 12,047 77
Community sensitisation 899 3 462 3
Trainingb 2,579 9 1,141 7
Supervision 4,453 16 1,788 11
Allowances for CHWs 10,349 37 5,546 35
Equipment for CHWs 2,334 8 1,251 8
mRDTs supplied 933 3 0 0
ACTs prescribed 72 0 1,078 7
Other supplies 1,177 4 748 5
Completed referrals to public health centres 175 1 33 0
CHW cost (value of time) per 1000 children 579 2 333 2
Overhead activitiesc 454 2 230 1
Diagnosis and treatment 125 0 103 1
Household cost per 1000 children 4,374 16 3,262 21
CHW visit (initial visit) 164 1 14 0
Completed referrals to public health centres 49 0 9 0
Drugs, fees, travel (private sector visits) 1,371 5 439 3
Special food to improve health 960 3 1,200 8
Opportunity cost of time lost 1,829 7 1,600 10
Total societal costs per 1000 children 27,925 100 15,642 100
Incremental analysis
(Replace presumptive diagnosis by mRDT diagnosis
in 1000 children suspected of malaria)
Incremental number of appropriately treated [95% CI] 822 [795; 848]
Incremental health sector cost, US$[95% CI] 10,924 [10,878; 10,973]
Incremental societal cost, US$[95% CI] 12,283 [2,783; 21,759]
ICER health sector perspective, US$[95% CI] 13.3 [12.9; 13.8]
ICER societal perspective, US$[95% CI] 14.9 [3.4; 26.4]
aChild with a positive reference diagnosis prescribed an ACT or child with a negative reference diagnosis not prescribed an ACT.
bIncluding cost of initial period of close support supervision.
cQuarterly review meetings, collection of supplies, communication with supervisors, etc.
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treatment services provided by CHWs, including data on the health
sector and household costs arising from reduced use of ACTs and
clinical management of mRDT negative patients, in addition to im-
plementation costs. Use of data derived from randomised trials, per-
mits measurement of the extra (incremental) cost and effects if
mRDTs were supplied to CHWs who previously prescribed ACT
treatment to children under five based on presumptive diagnosis;
whilst a common methodology across the two trials generates com-
parable data on costs and cost-effectiveness for two contrasting
transmission settings within the same health system. In the
moderate-to-high transmission setting, the incremental cost per add-
itional child appropriately treated by CHWs using mRDTs and
ACTs was low; at a total cost of US$3.0 from a health sector
perspective and US$3.6 from a broader societal perspective For
comparison, this is substantially lower than the range of health sec-
tor cost of US$5.0 to US$18.6 per appropriately treated patient of
introducing mRDTs in public health centres found in different
African countries (Batwala et al. 2011; Ansah et al. 2013;
Mangham-Jefferies et al. 2014; Tawiah et al. 2016). An important
explanation for the very low ICER of allowing trained CHWs to
utilise mRDTs was the substantial improvement in the appropriate
targeting of ACT treatment from 31% in the presumptive arm to
79% in the mRDT arm (48% points) seen in this trial. As a result of
these low incremental cost-effectiveness ratios, the introduction of
mRDT diagnosis is likely to be considered cost-effective, but as
pointed out by Marseille et al. (2015) it is up to government policy
Table 2a. Sensitivity to selected parameters of the incremental cost-effectiveness ratio (ICER) of replacing presumptive diagnosis by rapid
diagnostic tests performed by community health workers in moderate-to-high transmission area, Rukungiri District, Uganda, 2011
(US$1¼UGX2523)
—- ICER in US$—- —- ICER in US$—-
Health Health
Parametera sector Societal Parametera sector Societal
Malaria prevalence among Health centre cost for
customers (38% and 30%) treatment and diagnosis
10% 1.8 2.2 50% lower 2.9 3.5
20% 2.2 2.7 30% lower 2.9 3.6
40% 3.8 4.6 30% higher 3.1 3.7
50% 5.6 6.7 50% higher 3.1 3.7
Sensitivity of mRDT (73%) Probability of subsequent
60% 3.2 3.9 treatment-seeking in
80% 2.9 3.5 mRDT arm (9%)
90% 2.8 3.3 5% 3.0 3.3
100% 2.7 3.2 20% 3.0 4.4
Specificity of mRDT (83%) 30% 3.0 5.2
60% 4.7 5.5 Probability of subsequent
70% 3.8 4.5 treatment-seeking in
90% 2.7 3.3 presumptive arm (5%)
100% 2.3 2.8 10% 3.0 3.3
Adherence to negative 20% 3.0 2.5
mRDT (99%) 30% 3.0 1.8
60% 5.5 6.5 ACT price
70% 4.7 5.5 20% lower 3.3 3.9
80% 4.0 4.7 40% lower 3.6 4.2
Change in number of 50% lower 3.7 4.3
children visiting mRDT price (US$0.70)
CHWs in mRDT arm 20% lower 2.6 3.2
40% lower 8.4 9.1 40% lower 1.8 2.4
20% lower 5.0 5.7 50% lower 2.0 2.6
20% higher 1.7 2.2 Discount rate (3%)
40% higher 0.7 1.3 1% 3.0 3.6
Change in number of 7% 3.1 3.7
children visiting 10% 3.2 3.8
CHWs in presumptive arm Community sensitisation,
40% lower 0.8 0.3 training and intense
20% lower 1.6 2.2 supervision (every 5 years)
20% higher 4.0 4.6 Every 2 years 3.5 4.1
40% higher 4.6 5.3 Every 7 years 2.9 3.5
Probability of completed Opportunity cost
referral if negative per day (US$1.2)
diagnosis (8% and 0%) US$0.2 3.0 3.0
20% 3.3 4.1 US$0.6 3.0 3.2
40% 3.9 4.8 US$1.6 3.0 3.9
50% 4.1 5.2 US$2.0 3.0 4.1
aActual parameter value observed in the trial (Ndyomugyenyi et al. 2016) is shown in parenthesis.
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makers in individual countries to decide the cost-effectiveness
threshold below which the intervention will be regarded as cost-
effective.
In the low transmission area, an even larger improvement in ap-
propriate treatment for malaria from 8% to 90% (82% points) fol-
lowed the introduction of mRDTs. However, due to higher absolute
health sector costs in both arms and a large difference in costs be-
tween arms, the ICERs were much higher than in the moderate-to-
high transmission area. These cost characteristics could be explained
by substantially lower attendance in the low transmission area in par-
ticular the mRDT arm. While not formally investigated, possible ex-
planations for the low attendance rate might include the following:
low incidence of fever due to low malaria transmission, the presence
of an alternative health provider in the form of a mission hospital and
successful penetration during community sensitisation of the message
that ‘not all fevers are malaria’ possibly resulting in patients being less
likely to seek treatment from ‘malaria-only’ service providers like
CHWs in a low transmission area. This finding reveals that CHWs
are not a low cost service in all situations, confirming previous reports
from a multi-country study incorporating data from seven countries
in sub-Saharan Africa where areas with low utilisation CHW services
combined with significant fixed costs led to high cost per service
(Collins et al. 2014). Nonetheless, there may be ways of limiting the
cost of providing services in low transmission areas. Illustrative cost
calculations under the assumption that one CHW per village would
be sufficient resulted in considerably lower ICERs of US$5.4 and
US$6.9 from health sector and societal perspectives. Health policy
makers may therefore wish to adjust the number of CHWs according
to known transmission levels when planning community-based treat-
ment programmes incorporating mRDT diagnosis. If CHWs are
Table 2b. Sensitivity to selected parameters of the incremental cost-effectiveness ratio (ICER) of replacing presumptive diagnosis by rapid
diagnostic tests performed by community health workers in low transmission area, Rukungiri District, Uganda, 2011 (US$1¼UGX2523)
—- ICER in US$—- —- ICER in US$—-
Health Health
Parametera sector Societal Parametera sector Societal
Malaria prevalence among Health centre cost for
customers (6% and 6%) treatment and diagnosis
15% 16.2 18.2 50% lower 13.2 14.8
20% 18.3 20.6 30% lower 13.2 14.9
25% 21.1 23.7 30% higher 13.3 15.0
30% 24.9 28.0 50% higher 13.4 15.0
Sensitivity of mRDT (21%) Probability of subsequent
40% 13.1 14.8 treatment-seeking in
60% 13.0 14.6 mRDT arm (36%)
80% 12.8 14.4 5% 13.3 13.4
90% 12.7 14.3 20% 13.3 14.2
Specificity of mRDT (98%) 50% 13.3 15.6
60% 17.5 19.7 Probability of subsequent
70% 16.2 18.2 treatment-seeking in
80% 15.0 16.9 presumptive arm (11%)
90% 14.0 15.8 2% 13.3 15.4
Adherence to negative 20% 13.3 14.5
mRDT (95%) 30% 13.3 14.0
60% 21.9 24.6 ACT price
70% 18.6 20.8 20% lower 13.5 15.2
80% 16.1 18.0 40% lower 13.8 15.4
Change in number of 50% lower 13.9 15.5
children visiting mRDT price (US$0.70)
CHWs in mRDT arm 20% lower 13.0 14.7
40% lower 30.7 32.8 40% lower 12.6 14.2
20% lower 19.8 21.6 50% lower 12.7 14.3
20% higher 8.9 10.5 Discount rate (3%)
40% higher 5.8 7.3 1% 13.0 14.7
Change in number of 7% 13.8 15.5
children visiting 10% 14.2 15.9
CHWs in presumptive arm Community sensitisation,
40% lower 4.6 6.1 training and intense
20% lower 10.0 11.6 supervision (every 5 years)
20% higher 15.4 17.1 Every 2 years 16.5 18.1
40% higher 17.0 18.7 Every 7 years 12.7 14.3
Probability of completed Opportunity cost
referral if negative per day (US$1.2)
diagnosis (9% and 24%) US$0.2 13.3 14.5
20% 13.5 15.3 US$0.6 13.3 14.6
40% 14.0 15.9 US$1.6 13.3 15.1
50% 14.2 16.2 US$2.0 13.3 15.3
aActual parameter value observed in the trial (Ndyomugyenyi et al. 2016) is shown in parenthesis.
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trained to treat multiple common infections, such as for integrated
community case management (iCCM), this may lead to an overall in-
crease in attendance, even in areas of low malaria transmission and
subsequently result in a lower unit cost per patient treated.
Household cost constituted an important component of societal
costs in both transmission settings. The responses of caregivers dur-
ing interviews with respect to their out-of-pocket expenditure for
treatment-seeking, purchasing special food to improve the health of
the ill child and time unable to perform usual activities varied sub-
stantially, resulting in wide confidence intervals for incremental so-
cietal cost in both transmission settings. As a consequence, the
uncertainty facing the health policy maker in the decision to allow
CHWs to utilise mRDTs was much greater from a societal perspec-
tive compared to a more narrow health sector perspective. For ex-
ample, in the moderate-to-high transmission area, to reach a 95%
probability of mRDT use being cost-effective from a societal per-
spective would require a WTP of US$18.0 for each additional ap-
propriately treated child; whereas a low WTP of US$3.5 would be
sufficient to deem mRDTs cost-effective with almost 100% prob-
ability from a health sector perspective.
One of the frequently stated advantages of CHWs is that they in-
crease access to malaria treatment for community members and
lower costs of treatment-seeking. In the moderate-to-high transmis-
sion area of this study, households indeed experienced low out-of-
pocket expenditure for visiting CHWs, completing referral and add-
itional treatment-seeking in the private sector compared to house-
hold costs where individuals sought treatment at public health
centres in Ghana (Tawiah et al. 2016). However, the situation was
markedly different in the low transmission area where households
experienced much higher out-of-pocket expenditure especially in the
mRDT arm where the probability of additional treatment-seeking in
the private sector was 36% after visiting CHWs (versus 11% in the
presumptive arm). Visiting CHWs using mRDTs in a low transmis-
sion area, caregivers will more frequently be informed that the child
does not suffer from malaria thus leading to additional treatment-
seeking to treat the fever. Although the provision of a broader
Figure 2. Probabilistic sensitivity analysis from a health sector perspective, moderate-to-high transmission area, Rukungiri District: (a) scatter plot of incremental
health sector cost in US$ and incremental number of appropriately treated children resulting from replacing clinical diagnosis of malaria by rapid diagnostic test,
2011 (US$1¼UGX2,523) and (b) cost-effectiveness acceptability curve.
Figure 3. Probabilistic sensitivity analysis from a societal perspective, moderate-to-high transmission area, Rukungiri District: (a) scatter plot of incremental soci-
etal cost in US$ and incremental number of appropriately treated children resulting from replacing clinical diagnosis of malaria by rapid diagnostic test, 2011
(US$1¼UGX2,523) and (b) cost-effectiveness acceptability curve.
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service package like iCCM in which CHWs are also trained to treat
pneumonia and diarrhoea may diminish the number of febrile chil-
dren that cannot be treated at community level, it may not fully ob-
viate the need for additional treatment-seeking and resultant cost,
particularly in low malaria transmission settings.
Limitations
Data on household costs over a 14-day period were collected retro-
spectively through interviews with caregivers. Responses to ques-
tions regarding out-of-pocket expenditure and time utilisation
varied a lot in the sample resulting in standard deviations more than
double the mean value for many of the household cost categories.
This may reflect the methodological limitations inherent in this
retrospective approach, such as accuracy of recall, but may also re-
flect genuine variation in household behaviour when facing a sick
child with fever. The variation was larger than assumed in the
sample size calculation for the household cost interviews, and a
larger sample of household interviews would therefore have been de-
sirable to reduce uncertainty of the ICERs from a societal perspec-
tive in the form of narrower confidence intervals.
Conclusions
Availability of mRDTs among CHWs resulted in a substantial im-
provement in appropriate treatment of children compared to a situ-
ation with presumptive diagnosis in both transmission settings.
In the moderate-to-high transmission area this was achieved at low
cost, resulting in a low ICER from both health sector and societal
perspectives. In contrast, much higher health sector cost and ICERs
were found in the low transmission area reflecting the necessity that
significant resources must be invested in a programme before CHWs
can start offering their services, combined with low attendance for
malaria treatment. Costs could be substantially reduced if the
Figure 4. Probabilistic sensitivity analysis from a health sector perspective, low transmission area, Rukungiri District: (a) scatter plot of incremental health sector
cost in US$ and incremental number of appropriately treated children resulting from replacing clinical diagnosis of malaria by rapid diagnostic test, 2011
(US$1¼UGX2,523) and (b) cost-effectiveness acceptability curve.
Figure 5. Probabilistic sensitivity analysis from a societal perspective, low transmission area, Rukungiri District: (a) scatter plot of incremental societal cost in US$
and incremental number of appropriately treated children resulting from replacing clinical diagnosis of malaria by rapid diagnostic test, 2011 (US$1¼UGX2,523)
and (b) cost-effectiveness acceptability curve.
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number of CHWs per community who were focused on providing
malaria care was lower in areas with low attendance thus saving
some of the fixed costs related to individual CHWs such as training
and equipment.
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